Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNEU-STEM
2018-000066-11Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 15-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Merck & Co. Primary endpoint: Safety and tolerability following any of the 3 doses of V114 or Prevnar 13. Started Jun 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2018-000066-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000066-11.